



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Services Prior Authorization Criteria

SOVALDI® (sofosbuvir)

Effective 1/28/2016

[Prior Authorization Request Form](#)
[Prior Authorization Continuation Request Form](#)
[Patient Consent Form](#)
[Preferred HepC Regimens \(Attachment A\)](#)

Criteria for Approval

- 1) All documentation must be fully completed, including the patient consent form. A fibrosis score substantiated by a validated evidence-based method must be reported when requesting prior authorization; **AND**
- 2) Patient must have a documented **fibrosis level \geq F3**; **AND**
- 3) Patient must be eighteen (18) years of age or older; **AND**
- 4) Sovaldi must be prescribed by, or in conjunction with, a board certified gastroenterologist, hepatologist or infectious disease physician; **AND**
- 5) Patient must be diagnosed with chronic Hepatitis C Genotype 1, 2, 3, or 4; **AND**
- 6) Patient has abstained from the use of illicit drugs and alcohol for a minimum of three (3) months, as indicated by their signature on the Patient Consent form; **AND**
- 7) Patient must agree to complete the full regimen and the patient and the provider must agree that an SVR12 and SVR24 will be collected and submitted to WV Medicaid to verify therapy success;

Duration of Approval

- A list of accepted regimens and treatment duration for chronic Hepatitis C therapy may be found in [Attachment A](#).
- Initial approval is for 6 weeks.
- All indications require submission of an HCV RNA level at the start of therapy and at treatment week 4 (TW4).
- Continued coverage depends on documentation of patient compliance, continued abstinence and an HCV RNA < 25 IU/ml. **Failure to obtain and report a treatment week 4 HCV RNA load will result in denial of further coverage.**



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Diagnostic/Disease Severity Evidence (must be attached to request)

- 1) Cirrhosis may be substantiated either through biopsy or the presence of **at least two** of the following clinical features:
 - a. Cirrhotic features on imaging (MRI, ultrasound, or CT)
 - b. Ascites
 - c. Esophageal varices
 - d. Reversed AST:ALT ratio (> 1), thrombocytopenia ($< 130,000$ platelets/ μL), and coagulopathy (INR > 2)

Criteria for Denial

- 1) Requests submitted with incomplete documentation will be denied.
- 2) Failure to report a fibrosis score.
- 3) Evidence exists that the patient has abused any illicit substance or alcohol in the past three (3) months.
- 4) Patient has severe renal impairment (eGFR < 30 mL/min/1.73m²) or end stage renal disease (ESRD) requiring hemodialysis.
- 5) Patient is taking a concomitant medication that has a significant clinical interaction with sofosbuvir:
 - a. tipranavir/ritonavir
 - b. rifampin, rifabutin, rifapentine
 - c. carbamazepine, phenytoin, phenobarbital, oxcarbazepine
 - d. St. John's wort
- 6) Patient refuses treatment with Interferon but does not meet definition of Interferon Ineligibility. **Interferon Alfa Ineligible** is defined as:
 - a. Documented intolerance to previous trial of interferon
 - b. Autoimmune hepatitis and other autoimmune disorders
 - c. Hypersensitivity to peginterferon alfa or any of its components
 - d. Decompensated hepatic disease
 - e. A baseline neutrophil count below 1,500/ μL , a baseline platelet count below 90,000/ μL or baseline hemoglobin below 10 g/dL

Additional Considerations

- 1) It is highly recommended that the patient vaccinated against Hepatitis A and Hepatitis B.
- 2) Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor.
- 3) Coverage shall be for one successful course of therapy in a lifetime. Success of therapy shall be judged by undetectable SVR12 and SVR24 HCV RNA levels. If RNA levels have not been submitted, then it will be assumed that therapy was successful. Re-infection will not be covered. Exceptions may be allowed on a case-by-case basis.



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



- 4) Sofosbuvir combination treatment with ribavirin or peginterferon alfa/ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant because of the risks for birth defects and fetal death associated with ribavirin.
- 5) **For HCV/HIV co-infections all requests must be reviewed for drug-drug interactions prior to approval. Please submit a list of the patient's current HIV regimen along with your request for coverage of Sovaldi.**
- 6) Lost or stolen medication replacement request will not be authorized.

References

- 1) Sovaldi [package insert]. Foster City, CA; Gilead, August 2015.
- 2) AASLD 2015 Recommendations for Testing, Managing and Treating Hepatitis C (<http://www.hcvguidelines.org>) – Accessed 11/23/2015
- 3) FDA Antiviral Drugs Advisory Committee Meeting, October 25, 2013; Background Package for NDA 204671 sofosbuvir (GS-7977).
- 4) Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med*. 2013; 368:1878-87. doi: 10.1056/NEJMoa1214853. Available at: <http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214853>. Accessed January 2, 2014.
- 5) Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med*. 2013;368:1867-77. doi: 10.1056/NEJMoa1214854. Available at: <http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214854>. Accessed January 2, 2014.
- 6) American Association for the Study of Liver Diseases Infectious Diseases Society of America: Recommendations for testing, managing and treating hepatitis C. Available at: <http://www.hcvguidelines.org/>. Accessed February 18, 2014.
- 7) Poynard T, Ratziu V, Benmanov Y, DiMartino V, Bedossa P, Opolon P. Fibrosis in patients with hepatitis c: detection and significance. *Semin Liver Dis*. 2000;20(1). Retrieved from www.medscape.com. Accessed February 26, 2014.
- 8) Heidelbaugh JJ and Bruderly M. Cirrhosis and Chronic Liver Failure: Part I. Diagnosis and Evaluation. *Am Fam Physician*. 2006 Sep 1;74(5):756-762.